GUWAHATI: The Gauhati Medical College and Hospital (GMCH) here might be selected as one of the centres for the Phase-II trial of ‘Covaxin’, the country’s first indigenous vaccine. Hyderabad-based Bharat Biotech has ‘successfully completed’ Phase-I human clinical trials of the vaccine and Phase-II will start soon.
Informing about the development, Assam Health Minister Himanta Biswa Sarma said, “The Bharat Biotech has already started the process for selecting the centres for Phase-II testing of the vaccine. It is almost sure that GMCH will participate in the Phase-II trials,” said Sarma adding that the confirmation would be made official shortly.
He added that the paper works between Bharat Biotech and GMCH has already been going on.
The Drugs Controller General of India granted permission to Bharat Biotech for Phase-I and II human clinical trials after it had submitted results generated from preclinical studies, demonstrating safety and immune response.
Sarma said that unlike the prediction of the Centre, the COVID-19 death rate in Assam has not gone up. “The COVID-19 death rate has not risen in the manner that the Central had predicted. Our preparedness to combat the situation has yielded positive results,” he said.
With eight more deaths in the state due to COVID 19 on Thursday, Assam has registered at least 169 deaths so far. The total number of Assam’s COVID19 has shot up to 71795.